Premium
Lutein suppresses hyperglycemia‐induced premature senescence of retinal pigment epithelial cells by upregulating SIRT1
Author(s) -
Hwang Jung Seok,
Han Sung Gu,
Lee ChiHo,
Seo Han Geuk
Publication year - 2018
Publication title -
journal of food biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.507
H-Index - 47
eISSN - 1745-4514
pISSN - 0145-8884
DOI - 10.1111/jfbc.12495
Subject(s) - lutein , senescence , xanthophyll , retinal , retinal pigment epithelium , resveratrol , zeaxanthin , oxidative stress , reactive oxygen species , microbiology and biotechnology , diabetic retinopathy , sirtuin 1 , biology , endocrinology , downregulation and upregulation , medicine , carotenoid , pharmacology , biochemistry , diabetes mellitus , gene
Hyperglycemia contributes to the pathogenesis of diabetic complications, such as diabetic retinopathy, by affecting cellular redox state. In this study, we investigated the effects of lutein on hyperglycemia‐induced premature senescence in retinal pigment epithelium (RPE) cells. In ARPE‐19 cells, a spontaneously immortalized cell line derived from human RPE, lutein treatment significantly inhibited high glucose‐triggered premature senescence and production of reactive oxygen species (ROS). Notably, lutein treatment increased SIRT1 mRNA and protein levels, suggesting that lutein exerted its beneficial effects in these cells by upregulating SIRT1 expression. Resveratrol, an activator of SIRT1, mimicked the inhibitory effects of lutein on high glucose‐induced premature senescence and ROS generation, whereas sirtinol, a specific inhibitor of SIRT1, blocked these effects of lutein. Collectively, these observations indicate that lutein interferes with hyperglycemia‐induced RPE senescence by modulating SIRT1 signaling. Practical applications Lutein, a xanthophyll carotenoid present in green leafy vegetables and eggs, has been consumed as a dietary supplement to improve eye health. Lutein exhibited anti‐senescent properties by suppressing ROS generation through SIRT1 upregulation in RPE cells exposed to hyperglycemia mimicking diabetic conditions. Thus, we propose that lutein could be applied to therapeutic interventions aimed at treating hyperglycemia‐induced retinal disorders.